VIATRIS INC

Viatris lifts 2026 revenue outlook to $3.8B after Q2 loss, driven by new meloxicam sales, FDA‑approved eye drug, and a strategic divestiture.

Viatris raises 2026 revenue outlook after Q2 gains, sharpens focus on high‑margin generics & specialty products following a key divestiture and Tyrvaya sale.

Viatris Inc. navigates earnings, tariff risks and pain‑care growth—discover how U.S. drug tariffs and strategic shifts impact its future.

Viatris Inc faces shareholder pressure, a negative P/E, and a shifting biosimilar landscape—yet its AI‑cardiology potential could drive new growth and stabilize its future.

Viatris’s FDA‑accepted MR‑141 could unlock a new, non‑invasive presbyopia market, diversifying earnings and boosting stock value—will it succeed?

Viatris’ UBS upgrade spotlights disciplined capital allocation, rising profitability, and a strategic pipeline poised to boost shareholder value.

Viatris Inc. (VTRS) jumps after UBS upgrades to “Buy,” citing a strong biologics pipeline and emerging‑market expansion; institutional buying signals potential upside.

Viatris Inc. faces a critical crossroads as Biocon raises capital to buy its stake, sparking debate over whether divestiture will unlock value or dilute growth prospects for the Nasdaq‑listed drugmaker.

Viatris Inc shares near 52‑week high as institutional buys and JPMorgan conference spotlight its growth strategy and pipeline, signaling potential upside for investors.

Viatris Inc. announces a $0.12 quarterly dividend, Q3 earnings outlook and a new policy initiative to improve medicine access and health system resilience.